Company Update 1H24
PT Kalbe Farma Tbk
Table of Content
• | Key Updates | 04 |
• | Key Business Strategies | 07 |
• | Financial Overview | 20 |
• | Appendix 1 | 27 |
• | Appendix 2 | 34 |
Key Updates
2024 Key Strategies
Broad-based Growth with Emphasis on Higher Growth Categories
Prescription | Medical | |||||
Pharmaceuticals | Devices | |||||
Innovative Biologics products, | Build local manufacturing | |||||
including expanding Insulin | ||||||
capability | ||||||
business | ||||||
Strengthen our position | Strengthen network | |||||
in the market | and collaboration | |||||
Leverage Kalventis to | Accelerate | |||||
strengthen portfolio | ||||||
technology transfer | ||||||
in Vaccine | ||||||
International
Market
Bring more products to export markets
Focus to selected countries
Consumer Health
& Nutritionals
Expand into preventive and wellness category
Strengthen nutritional presence in affordable and ready-to-drink categories
Distribution
& Logistics
New potential principals
Integrated-FMCG cold chain business
Key Takeaways
Solid Foundation for Future Growth
Strategic Partnerships and Investments
7.6% | 1H24 Net | 18.4% | 1H24 EPS |
Sales growth | |||
growth |
New Product Development
Strategic Partnership with Alliance Pharma Co.,Ltd. (Thailand)
Key Updates
- Positive organic top-line growth in all business lines
- On-trackon key projects to sustain top line
- Sustained gross margin improvement trend
- Monitoring marketing effectiveness to drive growth
Key Risks
- Global financial and geopolitical volatility impact to currency and supply chain
- Temporary challenges in international market
Zerpidio and Efesa have been commercialized
Established JV Livzon Pharma Indonesia to manufacture pharmaceuticals ingredients
Radiopharmaceuticals facilities (cyclotron)
Local Content Requirement in medical devices for Dialyzer, Mobile X-Ray, CT- Scan, endoscopy, USG machine
Business Strategies
Corporate Overview
Market Capitalization
IDR 71.5 tn ($4.4 bn)*
free float
42.01%*
More than Half a Century of Providing Wide-Range Healthcare Solutions
The largest publicly-listed pharmaceuticals company in Southeast Asia
1966 | 1991 | Onwards |
Established, headquartered | Listed in the Indonesia | The most integrated |
healthcare company in | ||
in Jakarta | ||
Stock Exchange | ||
Southeast Asia | ||
Including treasury stocks
* As of 30 Jun 2024
Prescription
Pharmaceuticals
32.7% | 27.7% | ||
Net Sales | Consumer Health | ||
IDR 16,328 bn | |||
1H 2024 | Nutritionals | ||
(unaudited) | |||
14.2%
5%
Export
±40
Countries
Middle
EastSEA
South | |||
25.4% | Distribution & | Africa | |
Logistics |
Positive Net Sales Organic Growth Post-Pandemic
Prescription Pharmaceuticals
7.6%27.7%
Net Sales growth - 1H24 | Contribution |
to total net sales | |
From Rp4,196 bn to 4,516 bn | |
52.4%
Gross Profit Margin - 1H24
- Decreased from 53.5% in 1H23 due to product mix, remained stable from 52.4% in 1Q24
- ASP increase of 3% - 5% on selected products
13%
Market Share
Unbranded
Licensed
generics
27%
27%
Contribution
Branded generics 46%
*Source: Internal estimation
Kalbe
13%
a | |
9% | |
Market Share | b |
6% | |
others | c |
d4% | |
61% | |
e 4% | |
3% |
*Source: IQVIA 4Q23, in value
- No. 1 player in Indonesian prescription pharma market
- Performs better than pharma market
Driving Future Growth through Strategic Collaborations
Prescription Pharmaceuticals
Sustaining Business Expansion through Strategic Partnerships
Livzon Pharma Indonesia
Shareholder Agreement Signing Jul 2024
To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future
Exclusive Collaboration signing May 2024
To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand
JV establishment Dec 2022
To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar
Completion Dec 2022
To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines
Oncology
Biological-based
Other
Complete product range in all segments covering licensed, branded and unbranded generics
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |